Does cimetidine improve prospects for cancer patients? A reappraisal of the evidence to date

Claus Peter Siegers*, S. Andresen, J. P. Keogh

*Korrespondierende/r Autor/-in für diese Arbeit
16 Zitate (Scopus)


Background: Evidence first appeared in 1988 that cimetidine as an adjuvant may improve the survival of severely ill gastro-intestinal cancer patients when given peri- or postoperatively. Since then, several studies have appeared which suggest an anticancer activity for cimetidine, although few attempts have been made to corroborate their findings in large, placebo-controlled, double-blind studies. Method: We reviewed the literature concerning cimetidine's potential anticancer activity, particularly with regard to gastro-intestinal cancers. Results: Most studies suggest that cimetidine may improve the outcome in cancer patients by a three-pronged mechanism involving (1) inhibition of cancer cell proliferation; (2) stimulation of the lymphocyte activity by inhibition of T cell suppressor function, and (3) inhibition of histamine's activity as a growth factor in tumours. Conclusion: Bearing in mind the experimental evidence, as well as the potential and excellent safety profile of cimetidine, more studies are required and justified to clarify cimetidine's protherapeutic activity.

Seiten (von - bis)415-421
PublikationsstatusVeröffentlicht - 01.09.1999
Extern publiziertJa

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)


Untersuchen Sie die Forschungsthemen von „Does cimetidine improve prospects for cancer patients? A reappraisal of the evidence to date“. Zusammen bilden sie einen einzigartigen Fingerprint.